Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2010

Open Access 01-12-2010 | Research article

Assessment of the direct medical costs of diabetes mellitus and its complications in the United Arab Emirates

Published in: BMC Public Health | Issue 1/2010

Login to get access

Abstract

Background

Diabetes mellitus (DM) is a major health problem in the United Arab Emirates (UAE) and is well recognized as a major and increasing burden to the country's resources due to its severe, long term debilitating effects on individuals, families and the society at large. The aim of the study was to estimate the direct annual treatment costs of DM and its related complications among patients in Al-Ain city, UAE.

Methods

A sample of 150 DM patients were enrolled during 2004-2005, and their medical costs over the ensuing 12 months was measured, quantified, analyzed and extrapolated to the population in Al-Ain and UAE, using conventional and inference statistics. The costs were converted from UAE Dirhams to US Dollar, using the official conversion rate of US$ (1 USD = 3.68 AED).

Results

The total annual direct treatment costs of DM among patients without complications in Al Ain-UAE, was US $1,605 (SD = 1,206) which is 3.2 times higher than the per capita expenditure for health care in the UAE (US$ 497) during 2004 (WHO, 2004). However, this cost increased 2.2 times with the presence of DM related complications for patients with microvascular complications, by 6.4 times for patients with macrovascular complications and 9.4 times for patients with both micro and macrovascular complications. Likewise, the annual direct hospitalization costs of DM patients increased by 3.7 times for patients with microvascular complications, by 6.6 times for patients with macrovascular complications and by 5 times for patients with both micro and macrovascualr complications. Overall, costs increased with age, diabetes duration and were higher for patients treated with insulin compared to those treated with oral hypoglycemic agents or with diet control only.

Conclusions

DM direct treatment costs increased with the presence and progression of chronic DM related complications. Hospitalisation costs constituted a large proportion and were increasingly higher with the presence and progression of DM related complications. To reduce the impact on healthcare resources, efforts should be made to prevent progression to DM complications, by implementing guidelines for diabetes care, screening for complications and better management.
Appendix
Available only for authorised users
Literature
1.
2.
American Diabetes Association: Economic costs of diabetes in the U.S. In 2007. Diabetes Care. 2008, 31 (3): 596-615. 10.2337/dc08-9017.CrossRef
3.
Marchesini G, Forlani G, Rossi E, Berti A, De Rosa M, on behalf of the ARNO Working Group: The Direct Economic Cost of Pharmacologically-Treated Diabetes in Italy-2006. The ARNO Observatory. Nutr Metab Cardiovasc Dis. 2010
4.
Jonsson B, CODE-2 Advisory Board: Revealing the cost of Type II diabetes in Europe. Diabetologia. 2002, 45: S5-12. 10.1007/s00125-002-0858-x.CrossRefPubMed
5.
Malik M, Bakir A, Saab BA, King H: Glucose intolerance and associated factors in the multi-ethnic population of the United Arab Emirates: results of a national survey. Diabetes Res Clin Pract. 2005, 69 (2): 188-95. 10.1016/j.diabres.2004.12.005.CrossRefPubMed
6.
Al-Maskari F, El-Sadig M, Nelson NJ: The Prevalence of Macrovascular Complications among Diabetic Patients in Al-Ain District, United Arab Emirates. 2007, 6: 24-
7.
Al-Maskari F, El-Sadig M: Prevalence of Diabetic Retinopathy in the United Arab Emirates: A Cross-Sectional Survey. BMC Ophthalmol. 2007, 7 (11):
8.
Ministry of Health, United Arab Emirates: Annual Report. 2008, Preventive Medicine Sector, UAE
9.
Esteghamati A, Khalilzadeh O, Anvari M, Meysamie A, Abbasi M, Forouzanfar M, Alaeddini F: The economic costs of diabetes: a population-based study in Tehran, Iran. Diabetologia. 2009, 52 (8): 1520-7. 10.1007/s00125-009-1398-4.CrossRefPubMed
10.
Rekik M, Abid M, Hachicha J, Abbes R, Moujahed M, Jarraya A: Direct Costs of ambulatory management of diabetes at the outpatient clinic of the National Social Security Fund. Bulletin of the World Health Organization. 1994, 72: 611-614.PubMedPubMedCentral
11.
Arab M: Diabetes Mellitus in Egypt. World Health Statistics Quarterly. 1992, 45 (4): 334-7.
12.
Elrayah-Eliadarous H, Yassin K, Eltom M, Abdelrahman S, Wahlström R, Ostenson CG: Direct costs for care and glycaemic control in patients with type 2 diabetes in Sudan. Exp Clin Endocrinol Diabetes. 2010, 118 (4): 220-5. 10.1055/s-0029-1246216.CrossRefPubMed
13.
WHO: The Global Burden of Disease: 2004 updates. 2004
14.
15.
Weisbrod BA: Economics of Public Health. 1961, Philadelphia: University of Pennsylvania Press
16.
Rice DP, Cooper BS: Estimating the Cost of Illness. Health Economics Series No.6, PHS No.947-6. 1966, US Government Printing Office, Washington, DC
17.
Ettaro L, Songer TJ, Zhang P, Engelgau MM: Cost-of-illness studies in diabetes mellitus. Pharmacoeconomics. 2004, 22 (3): 149-64. 10.2165/00019053-200422030-00002.CrossRefPubMed
18.
Köster I, von Ferber L, Ihle P, Schubert I, Hauner H: The cost burden of diabetes mellitus: the evidence from Germany--the CoDiM study. Diabetologia. 2006, 49 (7): 1498-504. 10.1007/s00125-006-0277-5.CrossRefPubMed
19.
Brown JB, Nichols GA, Glauber HS, Bakst AW, Schaeffer M, Kelleher CC: Health care costs associated with escalation of drug treatment in type 2 diabetes mellitus. Am J Health Syst Pharm. 2001, 58 (2): 151-7.PubMed
20.
Henriksson F, Agardh CD, Berne C, Bolinder J, Lönnqvist F, Stenström P, Ostenson CG, Jönsson B: Direct medical costs for patients with type 2 diabetes in Sweden. J Intern Med. 2000, 248 (5): 387-96. 10.1046/j.1365-2796.2000.00749.x.CrossRefPubMed
21.
Khowaja LA, Khuwaja AK, Cosgrove P: Cost of diabetes care in out-patient clinics of Karachi, Pakistan. BMC Health Serv Res. 2007, 7: 189-10.1186/1472-6963-7-189.CrossRefPubMedPubMedCentral
22.
Barcelo A, Aedo C, Rajpathak S, Robles S: The cost of diabetes in Latin America and the Caribbean. Bull World Health Organ. 2003, 81 (1): 19-27.PubMedPubMedCentral
23.
Metadata
Title
Assessment of the direct medical costs of diabetes mellitus and its complications in the United Arab Emirates
Publication date
01-12-2010
Published in
BMC Public Health / Issue 1/2010
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/1471-2458-10-679

Other articles of this Issue 1/2010

BMC Public Health 1/2010 Go to the issue

Research article

Social status and cardiovascular disease: a Mediterranean case. Results from the Italian Progetto CUORE cohort study

Study protocol

Rationale and methods of the cardiometabolic valencian study (escarval-risk) for validation of risk scales in mediterranean patients with hypertension, diabetes or dyslipidemia

Study protocol

Understanding resilience in same-sex parented families: the work, love, play study

Study protocol

The Survey of the Health of Wisconsin (SHOW), a novel infrastructure for population health research: rationale and methods

Research article

Health-related quality of life, and its determinants, among older people in rural Vietnam

Research article

Evaluation of a community-based participatory physical activity promotion project: effect on cardiovascular disease risk profiles of school employees